Model reveals strategies to modify the tumor microenvironment and improve cancer therapy
Researchers from Mass General Brigham and the University of Cyprus have developed a mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC). The work is published in the Journal for ImmunoTherapy of Cancer.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
